Introduction
The United Kingdom remains an important market for pharmaceutical companies seeking to expand their commercial presence and make medicines available to patients. For foreign manufacturers, however, entering the UK involves more than obtaining approval in another country. Companies must identify the appropriate marketing authorisation pathway, establish an eligible applicant structure, prepare a compliant dossier and plan for ongoing regulatory responsibilities.
Understanding UK drug registration requirements at an early stage can help companies avoid unnecessary submission delays, documentation gaps and compliance issues. The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for assessing and authorising human medicines under the applicable UK regulatory framework.
The process may be more straightforward for companies whose products already have approval from a recognised overseas regulator, provided the product meets the eligibility criteria for the International Recognition Procedure (IRP). Other products may require a direct national application.
For companies considering drug registration in the UK for foreign companies, the key is to align the regulatory pathway, application documentation and local compliance arrangements before submission. This guide explains the main requirements, practical steps and considerations for preparing a successful UK market-entry strategy.
Understanding the UK Pharmaceutical Regulatory Framework
The MHRA regulates human medicines in the UK, assessing their quality, safety and efficacy before granting marketing authorisation. The main legal framework is the Human Medicines Regulations 2012, as amended, together with relevant MHRA guidance.
Since 1 January 2025, new marketing authorisations are generally UK-wide, covering Great Britain and Northern Ireland. The Windsor Framework changed the licensing arrangements for medicines, including products previously covered by the EU centralised procedure. Companies must therefore follow the current UK-wide licensing requirements rather than assume that separate Great Britain and Northern Ireland applications are available.
The principal MHRA drug registration requirements depend on the product, its legal basis and the proposed application route. Key considerations include:
- Product eligibility: Confirm that the product qualifies as a medicinal product and identify the appropriate legal basis for the application.
- Marketing authorisation holder: Ensure the proposed applicant meets the applicable establishment requirements.
- Dossier compliance: Prepare the required quality, non-clinical, clinical and administrative documentation.
- Pharmacovigilance: Establish the necessary safety-monitoring arrangements before authorisation.
- Product information: Ensure that the proposed Summary of Product Characteristics (SmPC), patient information leaflet (PIL) and labelling meet UK requirements.
An approval from the US Food and Drug Administration (FDA), European Medicines Agency (EMA) or another recognised authority does not automatically permit a medicine to be marketed in the UK. However, eligible overseas approvals may support an application through the IRP.
The MHRA’s official guidance on marketing a medicine in the UK provides the current application requirements and submission instructions.
UK Drug Registration Requirements for Foreign Companies
Foreign pharmaceutical manufacturers must address both the requirements for obtaining a UK marketing authorisation and the arrangements needed to maintain compliance after approval.
- Establish an eligible marketing authorisation holder (MAH)
The MAH must generally be established in the UK or EU/EEA. For IRP applications, MHRA expects the MAH to be the same legal entity as, or belong to the same corporate group as, the MAH for the reference-authority procedure. Third-party applicants may be accepted if they demonstrate that all legal obligations can be met. - Confirm pathway eligibility before submission
Assess whether the product qualifies for the national procedure or the International Recognition Procedure (IRP). An overseas approval alone is insufficient: the reference authority, approval date, product comparability and applicable route criteria must all be checked. - Align the UK dossier with the reference dossier
Prepare the required CTD/eCTD documentation, including UK-specific administrative information. For IRP, provide the reference regulator’s approval evidence and full, unredacted assessment reports, and ensure that the UK dossier reflects the consolidated dossier approved by that regulator. - Establish pharmacovigilance arrangements
Confirm the required qualified person responsible for pharmacovigilance (QPPV), pharmacovigilance system master file (PSMF) and safety-reporting processes. Where the QPPV does not reside and operate in the UK, a UK national contact person for pharmacovigilance is required. - Coordinate launch and lifecycle compliance
Plan for approved product information, packaging, manufacturing, importation and distribution. Assign responsibility for safety reporting, variations, renewals and ongoing regulatory commitments before launch.
Which Regulatory Pathway Should Foreign Companies Choose?
The appropriate route for UK pharmaceutical registration depends on the product, its regulatory history and whether it meets the MHRA’s eligibility criteria. Foreign companies should assess these factors before preparing their application.
| Pathway | When It May Be Suitable | Key Requirements | Indicative Assessment Timetable |
|---|---|---|---|
| National Assessment Procedure | Products that do not qualify for IRP or require direct MHRA assessment. | A complete application with the evidence required for the product and its legal basis. | Innovative medicines: a positive decision targeted within 150 clock-on days if issues are resolved after one round of questions, with a final decision by Day 210 where issues remain. Established medicines: final decision within 210 days, excluding clock-stops. |
| IRP Recognition Route A | Eligible products with a qualifying reference-authority approval granted within the previous two years. | Must meet Route A criteria, including applicable manufacturing and GMP requirements, and must not trigger Route B criteria. Full, unredacted reference assessment reports are required. | 60 calendar days after successful validation, with no clock-stop. If major concerns cannot be resolved within this period, the application may move to the Route B timetable. |
| IRP Recognition Route B | Eligible products with a qualifying reference-authority approval granted within the previous five years that meet one or more Route B criteria. | Full, unredacted reference assessment reports and supporting approval documentation. Additional assessment may be needed for manufacturing, clinical, safety or other specified differences. | 110 calendar days, with a possible clock-stop at Day 70 for up to 60 calendar days to respond to a request for further information. |
The IRP is available only when the product and reference-authority assessment meet the applicable requirements. The reference approval must be based on a full, standalone assessment rather than reliance on another jurisdiction’s approval. Applicants should complete the MHRA’s IRP eligibility process in advance and confirm the current requirements before submission.
Other specialised routes, including Project Orbis and Access Consortium procedures, may be relevant to eligible products but have their own criteria and timelines.
Step-by-Step UK Drug Registration Process
A structured approach helps foreign manufacturers coordinate regulatory, quality, clinical and commercial activities throughout the registration process.
Step 1: Confirm product classification and requirements
Determine whether the product falls under the UK medicines framework and identify the applicable authorisation requirements.
Step 2: Assess eligibility and select the pathway
Review regulatory history, previous approvals and product evidence to select the appropriate national, IRP or other eligible route.
Step 3: Conduct a dossier gap assessment
Identify missing data, inconsistencies and UK-specific documentation requirements.
Step 4: Prepare the application
Compile the required CTD/eCTD modules, application forms, product information and supporting documents.
Step 5: Validate and submit the dossier
Submit through the MHRA Submissions Portal after checking technical structure, document placement and administrative details.
Step 6: Respond to regulatory questions
Address MHRA queries with clear responses and supporting evidence within the specified deadlines.
Step 7: Prepare for launch and compliance
Implement approved product information and establish the required pharmacovigilance, manufacturing, importation and distribution arrangements.
Documents Required for UK Marketing Authorisation
The documentation required for UK marketing authorisation depends on the product type, legal basis and application pathway. A typical application includes the following:
- Administrative documentation: Application forms, applicant and MAH details, declarations, proposed product name and applicable fee information.
- Quality documentation: Drug substance and drug product information, manufacturing processes, specifications, analytical methods, stability data and relevant GMP documentation.
- Non-clinical evidence: Pharmacology, pharmacokinetic and toxicology services, where required for the product and legal basis.
- Clinical evidence: Clinical study reports, efficacy and safety data, summaries and relevant supporting analyses.
- Product information: Proposed SmPC, PIL and labelling in the required format.
- Pharmacovigilance documentation: Summary of the applicant’s pharmacovigilance system, QPPV details and PSMF information, as applicable.
- Reference-authority evidence for IRP: Approval decisions, full unredacted assessment reports and the required information about the reference-authority-approved dossier.
Additional documentation may be needed for application types. For example, where an active substance master file (ASMF) is referenced, the applicant must ensure that the relevant file has been submitted to the MHRA and that the necessary letter of authorisation is available. The dossier must follow the applicable eCTD technical requirements, including the UK-specific Module 1. For IRP applications, the submission must align with the consolidated dossier assessed and approved by the reference regulator, including relevant approved post-authorisation changes.
Applicants should use the MHRA’s current marketing authorisation application guidance and national assessment procedure guidance to confirm the documents required for their specific application.
UK Regulatory Requirements After Marketing Authorisation
Marketing authorisation does not end a company’s regulatory responsibilities. The MAH must maintain compliance throughout the product lifecycle and ensure that relevant safety, quality and product information remains up to date.
- Pharmacovigilance and safety reporting
The MAH must maintain an appropriate pharmacovigilance system and meet applicable requirements for individual case safety reports, periodic safety update reports (PSURs), risk management plans (RMPs) and post-authorisation safety studies (PASS), where relevant.
The required QPPV arrangements and PSMF must be maintained. Where the QPPV resides and operates outside the UK, the applicable UK national contact person requirement must also be met. - Variations and product information updates
Changes to manufacturing processes, product composition, indications, safety information or other authorised particulars may require a variation or another regulatory procedure. The company must determine the correct classification and follow the applicable submission and implementation requirements. - Renewals and authorisation maintenance
Companies must track renewal requirements, regulatory commitments and any conditions attached to the authorisation. The applicable renewal schedule depends on the marketing authorisation and relevant legal provisions.
Manufacturing, quality and supply-chain compliance
Relevant manufacturing, importation and distribution activities must meet applicable UK requirements. Quality defects, safety concerns and supply disruptions may trigger additional reporting or regulatory action. For foreign manufacturers, responsibilities should be clearly allocated between the MAH, manufacturing sites, local partners and service providers. DDReg’s UK pharmacovigilance services provide further information on support for relevant safety and compliance activities.
Common Challenges for Foreign Pharmaceutical Companies
Foreign manufacturers may face challenges even when their products have already been authorised in other markets.
| Key Challenge | What to Address |
|---|---|
| Pathway and MAH Eligibility | Confirm IRP eligibility and applicable UK/EU/EEA establishment requirements. |
| Dossier Gaps and Alignment | Ensure complete documentation, consistent product information and alignment with the reference-authority-approved dossier. |
| Pharmacovigilance Readiness | Establish compliant QPPV, PSMF and safety-reporting arrangements. |
| Launch Readiness | Align labelling, packaging, manufacturing and distribution with UK requirements. |
| Regulatory Changes | Monitor updated MHRA guidance and pathway criteria that may affect eligibility or submissions. |
How Foreign Companies Can Prepare for UK Market Entry
Foreign manufacturers can improve their readiness by completing a structured assessment before submitting a marketing authorisation application.
Foreign-company UK market-entry readiness checklist
| Checklist Item | Key Action |
|---|---|
| MAH Eligibility | Confirm UK/EU/EEA establishment requirements. |
| Registration Pathway | Select IRP Recognition A/B, national or another applicable route. |
| Dossier Alignment | Verify reference dossier alignment and assessment report availability. |
| Dossier Readiness | Check quality, clinical, non-clinical and administrative requirements. |
| eCTD Readiness | Validate submission structure and UK-specific documents. |
| Pharmacovigilance | Confirm QPPV, PSMF and UK contact arrangements, where applicable. |
| Timeline Planning | Allow for assessment, validation and potential queries. |
| Launch Preparation | Align product information, packaging, manufacturing and distribution. |
| Post-Approval Compliance | Assign responsibility for safety reporting, variations, renewals and commitments. |
Completing this checklist helps companies identify gaps before submission and make informed decisions about the resources and timelines needed for UK market entry.
How Regulatory Affairs Consulting Can Support UK Market Entry
Regulatory affairs consulting can help foreign pharmaceutical companies interpret MHRA requirements, select an appropriate pathway and coordinate the work needed to support a compliant application.
Support may include:
- Regulatory strategy and pathway assessment: Evaluating national and international recognition routes against product eligibility and business objectives.
- Regulatory gap analysis: Identifying missing documentation, dossier inconsistencies and UK-specific requirements before submission.
- Dossier preparation and publishing: Coordinating CTD/eCTD documentation, technical validation and submission readiness.
- Submission and assessment support: Managing application milestones, coordinating responses to regulatory questions and tracking commitments.
- Pharmacovigilance planning: Supporting applicable QPPV, PSMF, safety-reporting and post-authorisation arrangements.
- Lifecycle management: Coordinating variations, renewals, product information updates and regulatory intelligence.
DDReg supports pharmaceutical companies with UK market-entry planning, product registration, dossier preparation, submission management and post-approval compliance through its UK pharmaceutical regulatory services.
The level of support required depends on the product, the company’s existing regulatory capabilities and the selected application pathway. An early assessment can help establish a practical submission plan and identify potential issues before they affect the registration process.
Conclusion
Entering the UK pharmaceutical market requires a clear understanding of MHRA requirements, the appropriate marketing authorisation pathway and the obligations that continue after approval. For foreign manufacturers, applicant eligibility, dossier quality, pharmacovigilance readiness and launch planning must be addressed as part of one coordinated regulatory strategy.
The national procedure provides a route for direct MHRA assessment, while the International Recognition Procedure may be suitable for eligible products with qualifying overseas approvals. Neither route removes the need to meet applicable UK requirements or obtain the required marketing authorisation.
A structured approach to UK drug registration requirements helps companies select an appropriate pathway, prepare complete submissions and establish the systems needed to maintain compliance after launch.
Frequently Asked Questions
Yes, provided the application meets the applicable requirements. The marketing authorisation holder must generally be established in the UK or EU/EEA. A company headquartered elsewhere may need an eligible group company or an appropriate partner arrangement.
No. An overseas approval does not automatically authorise a medicine for sale in the UK. However, a qualifying approval from an MHRA-recognised reference regulator may support an application through the International Recognition Procedure, subject to the applicable eligibility and documentation requirements.
The timeline depends on the application pathway and product type. Under the MHRA’s national procedure, a positive decision for an innovative-medicine application is targeted within 150 clock-on days if issues are resolved after one round of questions. If issues remain at Day 150, the MHRA aims to reach a final decision as soon as possible and within 210 clock-on days. Established-medicine applications have a target final decision within 210 days, excluding regulatory clock-stops. Under the International Recognition Procedure (IRP), Recognition Route A has a 60-calendar-day timetable, while Recognition Route B has a 110-calendar-day timetable. These are regulatory assessment timetables, not guaranteed end-to-end launch timelines; validation, clock-stops where applicable and launch preparations can affect the overall duration.
Applications generally include administrative forms, quality documentation, non-clinical and clinical evidence as applicable, proposed product information, pharmacovigilance information and an eCTD dossier. IRP applications also require evidence of the reference-authority approval and full, unredacted assessment reports. The precise documentation depends on the product, legal basis and selected pathway.